19th July 2025 (15 Topics)
1
Jul
2
Jul
3
Jul
4
Jul
5
Jul
7
Jul
8
Jul
9
Jul
10
Jul
11
Jul
12
Jul
14
Jul
15
Jul
16
Jul
17
Jul
18
Jul
19
Jul
21
Jul
WHO Endorses Injectable Lenacapavir
Context
The World Health Organization (WHO) has released new guidelines recommending injectable lenacapavir (LEN) as a twice-yearly pre-exposure prophylaxis (PrEP) option for HIV prevention, announced during the IAS 2025 Conference in Kigali, Rwanda.
Lenacapavir (LEN):
- LEN is the first long-acting injectable PrEP approved for biannual administration to prevent HIV.
- Offers an alternative to daily oral PrEP (e.g., tenofovir-based regimens) and injectable cabotegravir (CAB-LA).
- Demonstrates high efficacy in clinical trials with minimal adherence challenges due to only two doses required per year.
Significance of WHO Recommendation:
- Addresses persistent HIV incidence (1.3 million new cases in 2024), particularly among key populations (e.g., sex workers, men who have sex with men, transgender individuals, injecting drug users).
- Enhances accessibility and acceptability of PrEP by reducing stigma and healthcare visit frequency.
More Articles
Courses
Study
Notes
Home
Resources
More
